| Name | Title | Contact Details |
|---|
Since day one, we`ve been dedicated to delivering personalized, innovative, and impactful workplace wellness programs. Provant is a health and wellness solutions company that partners with businesses to build cultures of health designed to improve the health, well-being, and productivity of employees while supporting employers with their healthcare affordability agenda. Provant`s Life+ Program combines personalized “high touch” services with powerful social networking tools that link rewards to healthy behaviors and outcomes. The results of these programs: exceptional engagement, improved health, productive employees, and lower costs. Founded in 2001, Provant serves customers of all sizes across the United States, Puerto Rico, Canada, and the Caribbean. Our customizable program is delivered to millions of people and consist of assessment services (e.g. screening services, flu vaccinations), inspirational services (e.g. coaching, lifestyle and condition programs) and reward and reporting services (participation-based and outcome-based programs). Program innovation, customization, and a comprehensive, quality approach to managing health risks are at the cornerstone of everything that we do. Our leadership team consists of seasoned wellness and business professionals with extensive experience in the health promotion, wellness, consumerism, medical, insurance, and hospital arenas. Our commitment to what we do is based on a sincere desire to promote wellness, to partner with our clients, and to work as a team. Improving lives in the process is what makes it all worthwhile.
Founded in 2017, Sift Healthcare is a Milwaukee-based healthcare payments analytics and data science company. Sift`s Payments Intelligence Platform, machine learning integrations and Rev/Track Insights Suite enable healthcare providers and payers to fully leverage their payments data to accelerate insurance reimbursement, improve patient payment strategies and optimize revenue cycle efficiency.
Neurostream Technologies is a Saint-Augustin-De-Desmaures, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.